CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting CAR T-cells in Patients With Relapsed and Refractory B-cell Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05836896
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:24.890789+00:00
Published At: 2025-08-24T00:00:00+00:00
Record Updated At: 2025-08-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Neoplasms", "Relapsed Diffuse Large B-cell Lymphoma (DLBCL)", "Refractory Diffuse Large B-cell Lymphoma (DLBCL)", "Multiple Myeloma, Refractory", "Multiple Myeloma in Relapse"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-24"
protocolSection.identificationModule.nctId: "NCT05836896"
protocolSection.identificationModule.officialTitle: "A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting CAR T-cells in Patients With Relapsed and Refractory B-cell Malignancies"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.